Market Closed - Australian S.E. 01:38:47 2024-04-26 am EDT 5-day change 1st Jan Change
0.008 AUD 0.00% Intraday chart for Memphasys 0.00% -33.33%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Memphasys Secures Additional Order for Fertility Device System in Japan; Shares Jump 9% MT
Memphasys Completes Trial of Animal Fertility System MT
Memphasys' Entitlement Offer Undersubscribed MT
Memphasys Signs Distribution Deals for Fertility System; Shares Jump 8% MT
Memphasys Receives AU$1.3 Million R&D Tax Rebate MT
India Records 10 More Live Births Using Memphasys' Fertility Device MT
Vitrolife Japan Places Initial Order for Memphasys' Felix System MT
Memphasys Signs Exclusive Japan Distribution Deal for Reproductive Device; Shares Surge 23% MT
Memphasys Secures Two New Australian Patents for the Felix System MT
Study Reveals Advantage of Memphasys' Felix System in Recovering Sperm Post Cryopreservation; Shares Jump 19% MT
Memphasys Sells Units of Sperm Separator Device in Japan; System Achieves First Live Birth; Shares Jump 6% MT
Memphasys Validates Efficacy of Fertility Device MT
Memphasys Secures Court Clearance, to Start Capital Raise MT
Memphasys' Felix System Found to be Superior to IVF Procedure DGC MT
Memphasys Appoints Nonexecutive Chair; Shares Fall 3% MT
Memphasys' Horse Fertility Diagnostic Device Achieves Up to 90% Accuracy Rate MT
Memphasys Receives ISO 13485 Compliance for Quality Management System MT
Memphasys to Start Clinical Trial for Bio-Separator Device; Shares Jump 8% MT
Memphasys Completes Field Trial for Horse Fertility Diagnostic Device MT
Memphasys Makes Maiden Sale of Sperm Separating Device MT
Memphasys : Receives $1 Million R&D Tax Refund; Secures China Sperm Separation Patent MT
Memphasys : Advances Development of Animal Reproductive Device MT
Memphasys' : Upgraded Felix Device Passes Internal Verification MT
Memphasys : Secures $2.3 Million Via Convertible Bond Issue MT
Memphasys : Progresses Development of Reproductive Biotechnology Portfolio MT
Chart Memphasys
More charts
Memphasys Limited is an Australia-based reproductive biotechnology company. The Company is engaged in developing novel medical devices, diagnostics, and media with applications to assisted reproduction technology (ART) in humans and animals. Its reproductive biotechnology products in development include medical devices, in vitro diagnostics, and new proprietary media. The Company's product pipeline includes Felix, ROSA, and AI-Port. The Felix is a patented, automated device for quickly separating high quality sperm from semen for use in human in vitro fertilization (IVF) procedures without causing damage to DNA. Felix has a sizable target market worldwide. The Company’s ROSA is an in vitro diagnostic that assesses semen and blood samples for the presence of oxidative stress. The AI-Port stores and transports animal semen for artificial insemination (AI) for up to four days without the harmful effects of freezing sperm used in standard AI procedures in livestock.
More about the company
  1. Stock Market
  2. Equities
  3. MEM Stock
  4. News Memphasys
  5. Memphasys Receives AU$1.3 Million R&D Tax Rebate